NR4A1 and breast carcinoma: The anti‐tumor effect of endocrine therapy can only be achieved when the breast cancer is hormone receptor positive.[18] To investigate whether POU4F1 knockout‐induced functional ERα re‐expression might resensitize BLBC cell lines to anti‐estrogen therapy, we treated the breast cancer cell lines with tamoxifen, an antagonist of ERα.